159
Participants
Start Date
January 23, 2020
Primary Completion Date
July 26, 2022
Study Completion Date
December 14, 2022
SPN-812
SPN-812 200 to 600 mg/day
Altea Research Institute, Las Vegas
Bioscience Research, Mount Kisco
iResearch Atlanta, Decatur
Psych Atlanta, Marietta
Atlanta Center for Medical Research, Atlanta
Clinical Neuroscience Solutions, Inc, Jacksonville
Florida Clinical Research Center, LLC, Maitland
Medical Research Group of Central Florida, Orange City
Clinical Neuroscience Solutions Inc., Orlando
CNS Healthcare, Orlando
Research Centers of America, Hollywood
Meridien Research, Tampa
Meridien Research, Lakeland
Gulfcoast Research Center, Fort Myers
Clinical Neuroscience Solutions, Memphis
St. Charles Psychiatric Associates Midwest Research Center, Saint Charles
Psychiatric Associates, Overland Park
Alivation Research, LLC, Lincoln
Paradigm Research Professionals, Oklahoma City
FutureSearch Trials of Dallas, LLP, Dallas
Houston Clinical Trials, Houston
Family Psychiatry of the Woodlands, The Woodlands
BioBehavioral Research of Austin P.C., Austin
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas
South California Research LLC, Beverly Hills
Collaborative Neuroscience Network LLC, Torrance
Pharmacology Research Institute, Los Alamitos
Artemis Research Institue for Clinical Research, Riverside
Artemis Institute for Clinical Rearch, San Marcos
Artemis Institute for Clinical Research, San Diego
Pharmacology Research Institute, Newport Beach
Collaborative Neuroscience Network, Garden Grove
Northwest Clinical Trials, Bellevue
Hassman Research Institute, Berlin
Center for Emotional Fitness, Cherry Hill
Hassmann Research Institute, Marlton
Princeton Medical Institute, Princeton
The Medical Research Network LLC, New York
Supernus Pharmaceuticals, Inc.
INDUSTRY